Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
grade D 36.34 2.71% 0.96
XNCR closed up 2.71 percent on Monday, September 16, 2019, on 42 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical XNCR trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
200 DMA Resistance Bearish 2.71%
1,2,3 Retracement Bearish Bearish Swing Setup 2.71%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.71%
Inside Day Range Contraction 2.71%
Fell Below 200 DMA Bearish 2.42%
1,2,3 Retracement Bearish Bearish Swing Setup 2.42%

Older signals for XNCR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Immune System Monoclonal Antibodies Autoimmune Diseases Rheumatoid Arthritis Antibody Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement
Is XNCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 46.65
52 Week Low 27.75
Average Volume 347,843
200-Day Moving Average 35.5551
50-Day Moving Average 40.5032
20-Day Moving Average 37.007
10-Day Moving Average 35.717
Average True Range 1.7856
ADX 31.83
+DI 13.905
-DI 26.3026
Chandelier Exit (Long, 3 ATRs ) 36.9232
Chandelier Exit (Short, 3 ATRs ) 39.3568
Upper Bollinger Band 40.7658
Lower Bollinger Band 33.2482
Percent B (%b) 0.41
BandWidth 20.313995
MACD Line -1.237
MACD Signal Line -1.3218
MACD Histogram 0.0848
Fundamentals Value
Market Cap 1.71 Billion
Num Shares 46.9 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -41.77
Price-to-Sales 29.06
Price-to-Book 3.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 38.95
Resistance 3 (R3) 38.84 37.85 38.52
Resistance 2 (R2) 37.85 37.19 37.91 38.37
Resistance 1 (R1) 37.10 36.77 37.47 37.21 38.22
Pivot Point 36.11 36.11 36.30 36.17 36.11
Support 1 (S1) 35.36 35.45 35.73 35.47 34.46
Support 2 (S2) 34.37 35.03 34.43 34.31
Support 3 (S3) 33.62 34.37 34.17
Support 4 (S4) 33.73